Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals
about
Bacteriophage Procurement for Therapeutic PurposesBiocontrol and Rapid Detection of Food-Borne Pathogens Using Bacteriophages and EndolysinsCharacterization and comparative genomic analysis of a novel bacteriophage, SFP10, simultaneously inhibiting both Salmonella enterica and Escherichia coli O157:H7Strain Specific Phage Treatment for Staphylococcus aureus Infection Is Influenced by Host Immunity and Site of InfectionRomulus and Remus, two phage isolates representing a distinct clade within the Twortlikevirus genus, display suitable properties for phage therapy applicationsFirst complete genome sequence of two Staphylococcus epidermidis bacteriophages.Salmonella enterica phage-resistant mutant colonies display an unusual phenotype in the presence of phage Felix 01.Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system.Glycosylation of wall teichoic acid in Staphylococcus aureus by TarM.Improving the safety of Staphylococcus aureus polyvalent phages by their production on a Staphylococcus xylosus strain.A novel bacteriophage Tail-Associated Muralytic Enzyme (TAME) from Phage K and its development into a potent antistaphylococcal proteinThe recombinant phage lysin LysK has a broad spectrum of lytic activity against clinically relevant staphylococci, including methicillin-resistant Staphylococcus aureusPhage treatment of human infections.Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation.Susceptibility of Staphylococcus epidermidis planktonic cells and biofilms to the lytic action of staphylococcus bacteriophage K.Potential of bacteriophage ΦAB2 as an environmental biocontrol agent for the control of multidrug-resistant Acinetobacter baumannii.Two Phages, phiIPLA-RODI and phiIPLA-C1C, Lyse Mono- and Dual-Species Staphylococcal Biofilms.Isolation of a Novel Phage with Activity against Streptococcus mutans Biofilms.The role of regulated clinical trials in the development of bacteriophage therapeutics.Isolation and Genome Characterization of the Virulent Staphylococcus aureus Bacteriophage SA97.Complete genome sequence of wide-host-range Staphylococcus aureus phage JD007In silico and in vivo evaluation of bacteriophage phiEF24C, a candidate for treatment of Enterococcus faecalis infections.Treatment of Staphylococcus aureus infections: new issues, emerging therapies and future directions.Characterization of novel Staphylococcus aureus lytic phage and defining their combinatorial virulence using the OmniLog® system.Bacteriophage and their lysins for elimination of infectious bacteria.Prospects of Phage Application in the Treatment of Acne Caused by Propionibacterium acnes.The Staphylococci phages family: an overviewMini-review: Staphylococcus epidermidis as the most frequent cause of nosocomial infections: old and new fighting strategies.In vitro activity against Staphylococcus aureus of a novel antimicrobial agent, PRF-119, a recombinant chimeric bacteriophage endolysin.Isolation, Characterization, and Antibacterial Activity of Bacteriophages Against Methicillin-Resistant Staphylococcus aureus in Pakistan.Phage Therapy: Future Inquiries.Phage Therapy in the Era of Synthetic Biology.Potential of bacteriophages and their lysins in the treatment of MRSA: current status and future perspectives.Role of SH3b binding domain in a natural deletion mutant of Kayvirus endolysin LysF1 with a broad range of lytic activity.Genomic analysis of Staphylococcus phage Stau2 isolated from medical specimen.Characterization and formulation into solid dosage forms of a novel bacteriophage lytic against Klebsiella oxytoca.Simultaneous Identification and Susceptibility Determination to Multiple Antibiotics of Staphylococcus aureus by Bacteriophage Amplification Detection Combined with Mass Spectrometry.Bacteriophage K for reduction of Staphylococcus aureusbiofilm on central venous catheter material.Isolation from sewage influent and characterization of novel Staphylococcus aureus bacteriophages with wide host ranges and potent lytic capabilities.Wide host range and strong lytic activity of Staphylococcus aureus lytic phage Stau2.
P2860
Q26738479-4228D144-A6E4-4AD9-931B-2F751F28B161Q26752523-369236E1-28CD-41CC-BEA6-739010BC25B5Q28395425-178294C2-1501-4984-9475-B39153D48EDAQ28546694-536B4735-A961-4A84-8A52-988C3C79D1C8Q30585271-B3D3CD50-646B-4782-BAF8-B41EAABB8083Q33266723-D35798FB-3125-40FE-9F19-07133874629BQ33301041-FA9F7693-D361-430E-868D-1B14DE58B625Q33509952-BD1AFF63-6925-49CB-8629-37DEDA5C8379Q33809923-69908919-A13E-4CCE-955E-938EDAAD902DQ33952220-1F251813-8967-4519-9B44-A8583362F66AQ34045132-27C53FB7-8D2F-4F7B-8373-6D73CB4CCE14Q34077249-9B85F20B-0731-469D-9422-424BA716760CQ34254407-669AF7BF-33BB-4694-BDFC-30BBF325E43EQ34594381-D8C8C633-FE13-4728-A80B-FE406C2BEBAAQ34667250-36722D1D-7546-4899-8820-CB5BCBB2DB00Q34802631-1D18CD02-B5AB-42AF-AF38-2BA93266FC3FQ35529858-09D516EC-28B1-49ED-8931-B9F43062B35FQ35785449-4FA694AD-803B-4B79-8A1A-59CD1EB87D03Q36135134-C314465C-08DC-4679-9628-B1B11E7609DEQ36246630-F9EF0D33-BFCD-4F80-9954-D9584DC2DD5AQ36414324-BF833684-26D8-496F-A865-7C90BD7289EBQ36746695-4CCAFE55-C1B8-4C2F-B2D3-F410B0D23F0AQ36758570-FF5C2645-1543-4855-9332-A4B66841074DQ37324738-F6F97F29-1D01-470C-B5BB-E3D0509BA6E7Q37470848-AF4802BD-CC1B-4D81-AAB6-0BDA53D4A2F7Q37629864-0260CE11-555F-4AB4-B288-5819C6BC744AQ38076134-1DEDB726-4E76-459E-8BF9-B9EBBEB44B13Q38166786-182BEC9B-C884-48A3-9173-8F8D4C2219D3Q38282871-D3E7CF83-A063-4264-91BA-C6A81B008166Q38784220-197C0B4B-A476-4B43-843D-F344F7FCC7EEQ38911928-CF02D92E-0EC3-406D-B9CA-9A1E91E9070AQ38915649-7022388A-6032-4981-A226-33C1717BC400Q39690702-BAE6CD76-4B97-49AD-A939-3041E825A3D9Q40065482-D4BA28EA-E9D6-46F8-9CC8-4647FDE4BD15Q40856467-12F227CB-1A1D-4B3B-B3A5-96440B567D2EQ41443659-9BCB23F6-14A8-4A8D-BA9E-53E81D14FB79Q41714250-433AC98E-3A6A-41DC-AA63-90260A404703Q41953340-0CFDB4AF-6B0F-4409-A3C8-E00D14515849Q41992228-D378C78B-7C8B-4F50-81CC-54A5011A714EQ42120556-9B6C8449-A904-4C46-9634-D212E729BF54
P2860
Potential of the polyvalent anti-Staphylococcus bacteriophage K for control of antibiotic-resistant staphylococci from hospitals
description
2005 nî lūn-bûn
@nan
2005 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Potential of the polyvalent an ...... t staphylococci from hospitals
@ast
Potential of the polyvalent an ...... t staphylococci from hospitals
@en
type
label
Potential of the polyvalent an ...... t staphylococci from hospitals
@ast
Potential of the polyvalent an ...... t staphylococci from hospitals
@en
prefLabel
Potential of the polyvalent an ...... t staphylococci from hospitals
@ast
Potential of the polyvalent an ...... t staphylococci from hospitals
@en
P2093
P2860
P1476
Potential of the polyvalent an ...... t staphylococci from hospitals
@en
P2093
G F Fitzgerald
M F Elbreki
S O'Flaherty
P2860
P304
P356
10.1128/AEM.71.4.1836-1842.2005
P407
P577
2005-04-01T00:00:00Z